- Trials with a EudraCT protocol (403)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
403 result(s) found for: mRNA.
Displaying page 1 of 21.
| EudraCT Number: 2022-000319-30 | Sponsor Protocol Number: SECTOR | Start Date*: 2022-03-09 |
| Sponsor Name:Institut Klinické a Experimentální Medicíny | ||
| Full Title: Assessment of association between 3rd dose of mRNA vaccine and risk of SARS-CoV-2 infection in kidney transplant recipients, safety and immunogenicity assessment. | ||
| Medical condition: SARS-CoV-2 infection in kidney transplant recipients; safety, effectiveness and immunogenicity of 3rd dose of SARS-CoV-2 mRNA vaccine. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000617-13 | Sponsor Protocol Number: TOR-VAX | Start Date*: 2022-04-12 | |||||||||||
| Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
| Full Title: A prospective, randomized, controlled trial assessing the effect of conversion from Tacrolimus-antimetabolite to Tacrolimus-mTor-inhibitors based immunosuppression to booster SARS-CoV-2-specific se... | |||||||||||||
| Medical condition: Seroconversion is evaluated after changing treatment from tacrolimus to tacrolimus + mTOR inhibitor in solid organ transplant patients who have not responded to the first three doses of the vaccine | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-002693-10 | Sponsor Protocol Number: VAC3_SARS-CoV2_seroconversion_study | Start Date*: 2021-07-15 |
| Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology | ||
| Full Title: A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination in Immunocompromised Patients with Inadequate Humoral Response after Primary mRNA SARS-CoV-2 (Covid-19) Vaccination | ||
| Medical condition: Vaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficiencies | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-004550-33 | Sponsor Protocol Number: APHP211184 | Start Date*: 2021-11-15 |
| Sponsor Name:Assistance publique Hopitaux de Paris/ DRCI | ||
| Full Title: Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pf... | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-020233-56 | Sponsor Protocol Number: DC-006 | Start Date*: 2011-03-24 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: PHASE I/II TRIAL OF VACCINE THERAPY IN RELAPSED AND PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS USING AUTOLOGOUS DENDRITIC CELLS LOADED WITH AMPLIFIED OVARIAN CANCER STEM CELL mRNA, hTE... | ||
| Medical condition: Relapsed and platinum resistant epithelial ovarian carcinoma patients that have received one line of non-platinum chemotherapy in resistance disease setting. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: NO (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-004788-29 | Sponsor Protocol Number: Covid_vacc_THL2021 | Start Date*: 2021-12-23 | |||||||||||
| Sponsor Name:Finnish Institute for Health and Welfare | |||||||||||||
| Full Title: COVID-19 vaccine immunological studies in Finland | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001993-52 | Sponsor Protocol Number: IMCOVAS | Start Date*: 2021-05-20 |
| Sponsor Name:University of Antwerp | ||
| Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc... | ||
| Medical condition: Coronavirus disease-19 (COVID-19) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-006253-41 | Sponsor Protocol Number: DC-004 | Start Date*: 2012-01-05 |
| Sponsor Name:The Norwegian Radium Hospital, Oslo University Hospital | ||
| Full Title: Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanoma | ||
| Medical condition: Malignant melanoma stage IV M1c or better | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-002348-57 | Sponsor Protocol Number: 2021-002348-57 | Start Date*: 2021-05-30 |
| Sponsor Name:Medical University of Vienna | ||
| Full Title: A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-Cov-2 Vaccines employed as Third Vaccination in Patients under current Rituximab The... | ||
| Medical condition: Vaccination against SARS-CoV-2 in patients with rituximab therapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-018770-20 | Sponsor Protocol Number: DC-005 | Start Date*: 2010-05-21 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving. | ||
| Medical condition: Prostatic cancer patients who have received curative surgery. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001974-33 | Sponsor Protocol Number: 08/014 | Start Date*: 2009-04-14 |
| Sponsor Name:Radboud University Nijmegen Medical Centre [...] | ||
| Full Title: mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients | ||
| Medical condition: Our study population consists of HLA-A2.1 positive patients with a high risk uveal melanoma (stage II) with proven expression of melanoma associated antigens tyrosinase and/or gp100. Patients are i... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000300-38 | Sponsor Protocol Number: 001610 | Start Date*: 2021-02-05 |
| Sponsor Name:Antwerp University Hospital | ||
| Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE) | ||
| Medical condition: Onco-hematological patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-002715-38 | Sponsor Protocol Number: APHP220775 | Start Date*: 2023-03-20 |
| Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
| Full Title: Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech... | ||
| Medical condition: Adults who received at least 3 doses of mRNA Covid 19 vaccine (BioNTech-Pfizer and/or Moderna), the last dose received at least 6 months prior to the inclusion in the trial. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002991-15 | Sponsor Protocol Number: SOLTI-1804 | Start Date*: 2019-11-04 |
| Sponsor Name:SOLTI | ||
| Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302 | ||
| Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-000924-14 | Sponsor Protocol Number: S52549 | Start Date*: 2011-05-23 |
| Sponsor Name:KU Leuven LRD | ||
| Full Title: Development and validation of a sputum biomarker mRNA panel for the diagnostic work-up of asthma | ||
| Medical condition: asthma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-002390-21 | Sponsor Protocol Number: Oxygen_Inflammation | Start Date*: 2013-09-03 |
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||
| Full Title: Effects of oxygen status on endotoxemia induced inflammation and Hypoxia Inducible Factor 1-a. A pilot proof of principle study. | ||
| Medical condition: Possible future indications: inflammatory conditions in general, autoimmune diseases | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002984-23 | Sponsor Protocol Number: 33-391ex20/21 | Start Date*: 2021-08-01 |
| Sponsor Name:Medical University of Graz | ||
| Full Title: Retrospective quantification of anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in patients treated with peritoneal dialysis | ||
| Medical condition: Chronic peritoneal dialysis patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000035-23 | Sponsor Protocol Number: VLA2001-307 | Start Date*: 2022-04-11 | |||||||||||
| Sponsor Name:Valneva Austria GmbH | |||||||||||||
| Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI... | |||||||||||||
| Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002724-83 | Sponsor Protocol Number: iHIVARNA-01 | Start Date*: 2017-02-22 | |||||||||||
| Sponsor Name:Erasmus MC | |||||||||||||
| Full Title: A phase IIa randomized, placebo controlled, double blinded study to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral t... | |||||||||||||
| Medical condition: Chronic HIV-1 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004513-90 | Sponsor Protocol Number: UMCN-AKF-14.07 | Start Date*: 2015-03-17 | |||||||||||
| Sponsor Name:Radboud UMC | |||||||||||||
| Full Title: Optimizing abiraterone (Zytiga®) therapy by exploring the relation between an early biomarker - drug exposure - as a predictor for drug response in patients with mCRPC (OPTIMUM - STUDY) | |||||||||||||
| Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
